Group 1: Viking Therapeutics - Viking Therapeutics is a mid-cap biotech focused on the weight management market, with positive phase 2 results for its leading candidate VK2735 and plans to move to phase 3 studies soon [2] - The potential for Viking is significant, as its candidate may not need to achieve the same sales as current leaders like Wegovy and Zepbound to be considered a success [3] - Viking is also developing additional candidates, including VK2809 for metabolic dysfunction-associated steatohepatitis and another weight loss candidate in preclinical studies, indicating a diversified pipeline [4] - The company is considered risky due to the lack of approved products, but its innovative approach could lead to substantial long-term gains if mid-stage programs succeed, with shares priced around $25 [5] Group 2: Exelixis - Exelixis is a successful cancer-focused biotech, recently announcing a label expansion for its best-selling product Cabometyx in treating advanced neuroendocrine tumors [6] - Cabometyx has been a significant growth driver, with Exelixis reporting a 18.5% year-over-year revenue increase to $2.2 billion and a 22% growth in adjusted net earnings per share to $2 [7] - The company resolved a legal battle regarding a potential Cabometyx generic, ensuring no competition from MSN Laboratories until 2030, allowing continued revenue growth from new indications [8] - Exelixis is developing new medicines, including zanzalintinib for advanced colorectal cancer, which is in phase 3 studies, addressing a high unmet need in the oncology market [10] - The ongoing performance of Cabometyx and Exelixis' robust pipeline suggest a strong long-term investment opportunity, with shares trading just under $37 [11]

Exelixis, Inc. (EXEL) announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib).The regulatory body approved Cabometyx for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET).Simultaneously, the drug was approved for adult and pediatric patients (12 years of age and older) with previously treated, unresectable, locally ...

Shares of Exelixis, Inc. (EXEL) have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also outperformed the sector and the S&P 500 Index in this timeframe. The company's upbeat performance can be attributed to its strong quarterly results, raised guidance and efforts to increase shareholders' returns.EXEL Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchLast month, Exelixis announced a new share repurchase program of $500 million. Shares rallied ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? Developed along ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Cancer drug specialist Exelixis (EXEL 5.02%) was quite the stock market star on Friday. Following news that it's making a big, shareholder-pleasing move, market players piled into the company to push its shares 5% higher on the day. This provided some light in what was generally a gloomy trading session, with the S&P 500 index falling by 1.7%.A $500 million moveAfter market close on Thursday, Exelixis announced that it will launch a new share repurchase program, authorized for up to $500 million worth of it ...

On Friday, Exelixis, Inc. EXEL authorized repurchasing up to an additional $500 million of the company’s common stock before December 31, 2025.Exelixis plans to complete the $500 million stock repurchase program, announced in August 2024, in the second quarter of 2025 and commence stock repurchases under the newly authorized stock repurchase program thereafter.As of the end of fiscal year 2024, Exelixis has returned over $1.2 billion to shareholders through these programs.Earlier this month, Exelixis report ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the task of finding cutting-edge growth stocks is made easy wit ...

Last week, Exelixis, Inc. (EXEL) reported better-than-expected fourth-quarter results.EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered adjusted earnings of 33 cents per share in the year-ago quarter. The outperformance was mainly driven by higher revenues.Including stock-based compensation expense, earnings were 48 cents per share in the reported quarter.Net revenues were $566.7 million, which beat the Zacks Consensus Estimate of $563 ...

Did you analyze how Exelixis (EXEL) fared in its international operations for the quarter ending December 2024? Given the widespread global presence of this drug developer, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For inves ...